WHO Functional Class IV Portopulmonary Hypertension After Prostacyclin Bridge Therapy Has Not Achieved Its Goals

This protocol applies when a patient with WHO functional class IV portopulmonary hypertension (PoPH), or pulmonary hypertension not meeting low-risk criteria, has been treated with prostacyclin agonist bridge therapy but has not reached the required hemodynamic and functional targets.

Clinical situation

Prostacyclin agonists (prostanoids) are the initial approach for patients in WHO functional class IV or for any patient with pulmonary hypertension not meeting low-risk criteria. This protocol addresses those patients whose disease has not been adequately controlled on that initial line of treatment.

Why this protocol is needed — prior therapy failure

Previous treatment: Prostacyclin agonist (prostanoid) as bridge therapy, together with supportive measures.

Goals not achieved: Adequate reduction of mean pulmonary arterial pressure and pulmonary vascular resistance; meaningful improvement in functional class and exercise tolerance (6-minute walking test).

When those targets are not reached, escalation to this next-line protocol is indicated.

Treatment approach — partial overview

The protocol escalates to triple therapy, adding agents from two further drug classes alongside the prostacyclin agonist. The complete regimen — including selection criteria, dosing, and sequencing — is in the full structured protocol.

Full regimen details, dosing, and algorithm not shown here.

Treatment targets

Success is defined as an adequate hemodynamic response: mean pulmonary arterial pressure below 35 mm Hg and pulmonary vascular resistance below 3 WU, confirmed on 3-month follow-up heart catheterization.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1097/TXD.0000000000001517

The prostacyclin agonists (prostanoids) are reserved for patients with a type IV functional class according to the World Health Organization or any patient with PH not meeting low-risk criteria.

They can also be used as triple therapy in FC IV patients.

Bosentan and Macitentan are endothelin A and B receptor antagonists, and Ambrisentan is a selective endothelin receptor A antagonist.

The AASLD guidelines suggest that OLT can be offered to patients with mild PoPH and those with an excellent response to medical treatment (MPAP after treatment <35 mm Hg and peripheral vascular resistance <3 WU).

View source ↗